{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": false, "customPriceAlertConfidence": "LOW", "currency": "EUR", "exchange": "FRA", "shortName": "OKYO PHARMA LTD SP.ADR/65", "longName": "OKYO Pharma Limited", "messageBoardId": "finmb_45535051", "exchangeTimezoneName": "Europe/Berlin", "exchangeTimezoneShortName": "CEST", "gmtOffSetMilliseconds": 7200000, "market": "dr_market", "esgPopulated": false, "marketState": "REGULAR", "regularMarketChangePercent": -12.080542, "regularMarketPrice": 1.31, "trailingAnnualDividendYield": 0.0, "epsTrailingTwelveMonths": -0.73, "sharesOutstanding": 25519900, "bookValue": 0.0, "fiftyDayAverage": 1.365, "fiftyDayAverageChange": -0.055000067, "fiftyDayAverageChangePercent": -0.04029309, "twoHundredDayAverage": 1.81685, "twoHundredDayAverageChange": -0.50685, "twoHundredDayAverageChangePercent": -0.27897185, "marketCap": 33431068, "sourceInterval": 15, "exchangeDataDelayedBy": 15, "tradeable": false, "cryptoTradeable": false, "firstTradeDateMilliseconds": 1653458400000, "priceHint": 4, "regularMarketChange": -0.18000007, "regularMarketTime": 1683875702, "regularMarketDayHigh": 1.31, "regularMarketDayRange": "1.31 - 1.31", "regularMarketDayLow": 1.31, "regularMarketVolume": 100, "regularMarketPreviousClose": 1.49, "bid": 1.33, "ask": 1.45, "fullExchangeName": "Frankfurt", "financialCurrency": "GBP", "regularMarketOpen": 1.31, "averageDailyVolume3Month": 2, "averageDailyVolume10Day": 0, "fiftyTwoWeekLowChange": 0.26, "fiftyTwoWeekLowChangePercent": 0.24761905, "fiftyTwoWeekRange": "1.05 - 2.84", "fiftyTwoWeekHighChange": -1.53, "fiftyTwoWeekHighChangePercent": -0.5387324, "fiftyTwoWeekLow": 1.05, "fiftyTwoWeekHigh": 2.84, "trailingAnnualDividendRate": 0.0, "symbol": "OK10.F"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "14/15 Conduit St", "address2": "Floor 4", "city": "London", "zip": "W1S 2XJ", "country": "United Kingdom", "phone": "44 20 7495 2379", "website": "https://www.okyopharma.com", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "OKYO Pharma Limited, a preclinical biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101 for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic ocular pain. The company was incorporated in 2007 and is headquartered in London, the United Kingdom.", "fullTimeEmployees": 7, "companyOfficers": [{"maxAge": 1, "name": "Dr. Gary S. Jacob Ph.D.", "age": 75, "title": "CEO & Exec. Director", "yearBorn": 1947, "fiscalYear": 2022, "totalPay": {"raw": 392637, "fmt": "392.64k", "longFmt": "392,637"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 189375, "fmt": "189.38k", "longFmt": "189,375"}}, {"maxAge": 1, "name": "Mr. Michael Paul Beck", "age": 65, "title": "Founder", "yearBorn": 1957, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Keeren  Shah", "age": 45, "title": "Chief Financial Officer", "yearBorn": 1977, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Rajkumar  Patil Ph.D.", "age": 64, "title": "Chief Scientific Officer", "yearBorn": 1958, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "compensationAsOfEpochDate": 1672444800, "maxAge": 86400}}], "error": null}}